Premium
Moving forward with breast cancer prevention
Author(s) -
Chen Wendy Y.,
Rosner Bernard,
Colditz Graham A.
Publication year - 2007
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22711
Subject(s) - medicine , breast cancer , selective estrogen receptor modulator , raloxifene , randomized controlled trial , cancer , clinical trial , incidence (geometry) , oncology , cancer prevention , gynecology , estrogen receptor , physics , optics
Despite randomized controlled trial data supporting the use of selective estrogen receptor modulators (SERMs) to reduce the incidence of breast cancer, to the authors' knowledge uptake has been limited. Similar to cardiovascular risk models, the routine use of breast cancer risk prevention models in the clinical setting to identify those patients at highest risk of developing breast cancer can maximize the risk‒benefit ratio of SERMs and provide an impetus to move forward with implementing breast cancer prevention.